A Comparative Phase IV Study Evaluating Efficacy & Safety Of Magnex(Cefoperazone-Sulbactam) In Intraabdominal Infections
Status:
Completed
Trial end date:
2005-04-01
Target enrollment:
Participant gender:
Summary
Intra-abdominal infections are often polymicrobial, and include aerobic as well as anaerobic
bacteria. Antibiotics used in intra-abdominal infections should aim to cover organisms such
as Enterobacteriaceae and Bacteroides fragilis, which are the commonest organisms known to
cause such infections. Combinations of a third-generation cephalosporin, an aminoglycoside
and metronidazole are often used to treat such infections in surgical settings. An
alternative to such combinations is the use of a beta lactam - beta lactamase inhibitor
combination. Magnex (cefoperazone- sulbactam) is one such combination, which has been shown
to be as effective as a standard multidrug regimen such as gentamicin and clindamycin in the
management of intra-abdominal infections. The combination of ceftazidime, amikacin and
metronidazole has been chosen as a comparator regimen because of its broad coverage of
Gram-negative and anaerobic organisms found in such conditions.